Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia

Journal of Viral Hepatitis

Volumn 18, Issue 4, 2011, Pages

  Grebely, Jason ^a   Bryant, J ^b   Hull, P ^b   Hopwood, M ^b   Lavis, Y ^b   Dore, G J ^a   Treloar, C ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antiviral therapy; Injecting drug use; Opiate substitution therapy; Provider; Treatment decisions

Indexed keywords

ADULT; ANTIVIRAL THERAPY; ARTICLE; AUSTRALIA; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL SPECIALIST; PATIENT EDUCATION; PRIORITY JOURNAL; SELF REPORT; SOCIAL SUPPORT; SYMPTOM;

ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; NEW SOUTH WALES; PATIENT ACCEPTANCE OF HEALTH CARE;

EID: 79952675044     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01370.x     Document Type: Article

References (49)

1. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Eng J Med 2002; 347(13): 975-982.
2. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358(9286): 958-965. (Pubitemid 32913521)
3. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Inter Med 2002; 136(4): 288-292. (Pubitemid 34150758)
4. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36(1): 97-100. (Pubitemid 36099103)
5. Groom H, Dieperink E, Nelson DB et al. Outcomes of a Hepatitis C screening program at a large urban VA medical center. J Clin Gastroenterol 2008; 42(1): 97-106.
6. Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med 2005; 20(8): 754-758. (Pubitemid 41141009)
7. Adeyemi OM, Jensen D, Attar B et al. Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. AIDS Patient Care STDS 2004; 18(4): 239-245. (Pubitemid 38552655)
8. Fishbein DA, Lo Y, Reinus JF, Gourevitch MN, Klein RS. Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. J Acquir Immune Defic Syndr 2004; 37(3): 1367-1375. (Pubitemid 39435051)
9. Jowett SL, Agarwal K, Smith BC et al. Managing chronic hepatitis C acquired through intravenous drug use. QJM 2001; 94(3): 153-158. (Pubitemid 32242003)
10. Restrepo A, Johnson TC, Widjaja D et al. The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre. J Viral Hepat 2005; 12(1): 86-90. (Pubitemid 40188779)
11. Mehta SH, Lucas GM, Mirel LB et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006; 20(18): 2361-2369. (Pubitemid 44789539)
12. Hallinan R, Byrne A, Agho K, Dore GJ. Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug Alcohol Depend 2007; 88(1): 49-53. (Pubitemid 46400306)
13. Kanwal F, Hoang T, Spiegel BM et al. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology 2007; 46(6): 1741-1749.
14. Bini EJ, Brau N, Currie S et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005; 100(8): 1772-1779. (Pubitemid 41648433)
15. Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56(3): 385-389. (Pubitemid 46579770)
16. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Pretreatment assessment and predictors of hepatitis C virus treatment in US veterans coinfected with HIV and hepatitis C virus. J Viral Hepat 2006; 13(12): 799-810. (Pubitemid 44748284)
17. Lettmeier B, Muhlberger N, Schwarzer R et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008; 49(4): 528-536.
18. NCHECR. HIV/AIDS, Viral Hepatitis and Sexually Transmissible Infections in Australia. Annual Surveillance Report 2009. Sydney: National Centre in HIV Epidemiology and Clinical Research, 2009.
19. Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009; 50(6): 1750-1755.
20. Rocca LG, Yawn BP, Wollan P, Kim WR. Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat. Ann Fam Med 2004; 2(2): 116-124. (Pubitemid 39329078)
21. Feuerstadt P, Bunim AL, Garcia H et al. Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. Hepatology (Baltimore, MD) 2010; 51(4): 1137-1143.
22. NCHECR. HIV/AIDS, Viral Hepatitis and Sexually Transmissible Infections in Australia. Annual Surveillance Report 2008. Sydney: National Centre in HIV Epidemiology and Clinical Research, 2008.
23. Grebely J, Raffa JD, Lai C et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009; 16(5): 352-358.
24. Mehta SH, Genberg BL, Astemborski J et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33(3): 126-133.
25. Hall CS, Charlebois ED, Hahn JA, Moss AR, Bangsberg DR. Hepatitis C virus infection in San Francisco's HIV-infected urban poor. J Gen Intern Med 2004; 19(4): 357-365.
26. Stoove MA, Gifford SM, Dore GJ. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Depend 2005; 77(1): 81-86. (Pubitemid 39656102)
27. Doab A, Treloar C, Dore GJ. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis 2005; 40(Suppl. 5): S313-S320. (Pubitemid 40490217)
28. Moss-Morris R, Weinman J, Petrie K, Horne R, Cameron L, Buick D. The Revised Illness Perception Questionnaire (IPQ-R). Psychol Health 2002; 17(1): 1-16.
29. Dahlem NW, Zimet GD, Walker RR. The multidimensional scale of perceived social support: a confirmation study. J Clin Psychol 1991; 47(6): 756-761.
30. Lang CA, Conrad S, Garrett L et al. Symptom prevalence and clustering of symptoms in people living with chronic hepatitis C infection. J Pain Symptom Manage 2006; 31(4): 335-344.
31. Gidding HF, Topp L, Middleton M et al. The epidemiology of hepatitis C in Australia: notifications, treatment uptake and liver transplantations, 1997-2006. J Gastroenterol Hepatol 2009; 24(10): 1648-1654.
32. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36(5 Suppl. 1): S35-S46. (Pubitemid 35253462)
33. Dore GJ, Hellard M, Matthews GV et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010; 138(1): 123-135.
34. Grebely J, Genoway KA, Raffa JD et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 2008; 93(1-2): 141-147. (Pubitemid 350245718)
35. Gupta L, Shah S, Ward JE. Educational and health service needs of Australian general practitioners in managing hepatitis C. J Gastroenterol Hepatol 2006; 21(4): 694-699.
36. Treloar C, Newland J, Harris M, Deacon R, Maher L. Providing a better hepatitis C diagnosis: insights from a qualitative study of recent seroconverters. Aust Fam Physician 2010; in press.
37. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19(3): 1-46.
38. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49(4): 561-573.
39. Treloar C, Newland J, Rance J, Hopwood M. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. J Viral Hepat 2010; doi: 10.1111/j.1365-2893.2009. 01250.x.
40. Treloar CJ, Fraser SM. Hepatitis C treatment in pharmacotherapy services: increasing treatment uptake needs a critical view. Drug Alcohol Rev 2009; 28(4): 436-440.
41. Strathdee SA, Latka M, Campbell J et al. Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis 2005; 40(Suppl. 5): S304-S312. (Pubitemid 40490216)
42. Becker MH, Maiman LA, Kirscht JP, Haefner DP, Drachman RH. The Health Belief Model and prediction of dietary compliance: a field experiment. J Health Soc Behav 1977; 18(4): 348-366. (Pubitemid 8251316)
43. Treloar C, Byron P, McCann P, Maher L. "Fitness for duty": social, organisational and structural influences on the design and conduct of candidate hepatitis C vaccine trials involving people who inject drugs. Vaccine 2010; 28(32): 5228-5236.
44. Fraenkel L, McGraw S, Wongcharatrawee S, Garcia-Tsao G. What do patients consider when making decisions about treatment for hepatitis C? Am J Med 2005; 118(12): 1387-1391.
45. Day C, Dolan K. Correlates of hepatitis C testing among heroin injectors in Sydney. Health Promot J Austr 2006; 17(1): 70-72.
46. Day CA, White B, Thein HH et al. Experience of hepatitis C testing among injecting drug users in Sydney, Australia. AIDS Care 2008; 20(1): 116-123. (Pubitemid 351264547)
47. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67(2): 117-123. (Pubitemid 34722399)
48. Grebely J, Knight E, Genoway KA et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol 2010; 22(3): 270-277.
49. Australian Government Department of Health and Ageing. National Hepatitis C Testing Policy. In: Hepatitis C Subcommittee of the Ministerial Advisory Committee on AIDS SHH, the Blood Borne Virus and Sexually Transmissible Infections Subcommittee of the Australian Population Health Development Committee, ed. Canberra, 2007.